share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K.

Novavax | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K.

诺瓦瓦克斯医药 | 4:持股变动声明-董事 King Rachel K.
美股sec公告 ·  06/14 16:30
Moomoo AI 已提取核心信息
Rachel K. King, associated with Novavax Inc [NVAX], completed a transaction on June 12, 2024, acquiring 6,670 shares of common stock at no cost. This transaction was classified as an exercise or conversion of derivative security, under the transaction code 'M'. Following this acquisition, King's direct holdings in Novavax common stock increased to a total of 18,920 shares. The transaction has been marked as completed.
Rachel K. King, associated with Novavax Inc [NVAX], completed a transaction on June 12, 2024, acquiring 6,670 shares of common stock at no cost. This transaction was classified as an exercise or conversion of derivative security, under the transaction code 'M'. Following this acquisition, King's direct holdings in Novavax common stock increased to a total of 18,920 shares. The transaction has been marked as completed.
2024年6月12日,诺瓦瓦克斯医药(Novavax Inc [NVAX])的Rachel K. King获得了6,670股普通股,无需支付任何费用。此次交易归类为衍生证券的行权或转换,交易代码为“M”。在此次收购之后,King在诺瓦瓦克斯医药普通股的直接持股增加到了18,920股。交易已标记为已完成。
2024年6月12日,诺瓦瓦克斯医药(Novavax Inc [NVAX])的Rachel K. King获得了6,670股普通股,无需支付任何费用。此次交易归类为衍生证券的行权或转换,交易代码为“M”。在此次收购之后,King在诺瓦瓦克斯医药普通股的直接持股增加到了18,920股。交易已标记为已完成。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息